Anti‐inflammatory effects of the petasin phyto drug Z e339 are mediated by inhibition of the STAT pathway

Ze339, an herbal extract from Petasites hybridus leaves is effective in treatment of allergic rhinitis by inhibition of a local production of IL‐8 and eicosanoid LTB 4 in allergen‐challenged patients. However, the mechanism of action and anti‐inflammatory potential in virally induced exacerbation of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BioFactors (Oxford) 2017-05, Vol.43 (3), p.388-399
Hauptverfasser: Steiert, Sabrina A., Zissler, Ulrich M., Chaker, Adam M., Esser‐von‐Bieren, Julia, Dittlein, Daniela, Guerth, Ferdinand, Jakwerth, Constanze A., Piontek, Guido, Zahner, Catherine, Drewe, Juergen, Traidl‐Hoffmann, Claudia, Schmidt‐Weber, Carsten B., Gilles, Stefanie
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Ze339, an herbal extract from Petasites hybridus leaves is effective in treatment of allergic rhinitis by inhibition of a local production of IL‐8 and eicosanoid LTB 4 in allergen‐challenged patients. However, the mechanism of action and anti‐inflammatory potential in virally induced exacerbation of the upper airways is unknown. This study investigates the anti‐inflammatory mechanisms of Ze339 on primary human nasal epithelial cells (HNECs) upon viral, bacterial and pro‐inflammatory triggers. To investigate the influence of viral and bacterial infections on the airways, HNECs were stimulated with viral mimics, bacterial toll‐like‐receptor (TLR)‐ligands or cytokines, in presence or absence of Ze339. The study uncovers Ze339 modulated changes in pro‐inflammatory mediators and decreased neutrophil chemotaxis as well as a reduction of the nuclear translocation and phosphorylation of STAT molecules. Taken together, this study suggests that phyto drug Ze339 specifically targets STAT‐signalling pathways in HNECs and has high potential as a broad anti‐inflammatory drug that exceeds current indication. © 2016 BioFactors, 43(3):388–399, 2017
ISSN:0951-6433
1872-8081
DOI:10.1002/biof.1349